Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

NCT04615143 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Hepatocellular Carcinoma

Interventions

DRUG: Tislelizumab
DRUG: Tislelizumab combined with Levatinib

Sponsor

Sun Yat-sen University